Platypus Technologies, LLC
5520 Nobel Drive, Suite 100
Madison, WI 53711
Madison, WI – Platypus Technologies announces that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant for $400,000 from the National Institutes of Health. This 2-year funded project will enable the Company to achieve greater sensitivity in detecting nitric oxide (NO) using its patented Liquid Crystal (LC) Technology. The levels of NO in exhaled human breath have been correlated with the severity of lung tissue inflammation associated with asthma. The Platypus® disposable NO sensor has already shown specificity for NO in the presence of other components abundant in human breath including oxygen, carbon dioxide, carbon monoxide, moisture, ammonia, and hydrogen disulfide. According to Renee Herber, Program Manager, “this is an exciting project that helps us to expand the types of analytes detectable by our technology and has the potential to move us into new commercialization opportunities.” Platypus Technologies has received over $18 million in federal funding to develop LC-based nanotechnology products for environmental monitoring, infectious disease testing and homeland security.
About Platypus Technologies, LLC:
Platypus Technologies, LLC develops innovative products for the analytical and life sciences that utilize recent advances in nanotechnology and material science. The Company is developing a range of products that derive from a proprietary platform technology utilizing liquid crystals for the rapid detection of molecular interactions. Platypus Technologies has successfully launched several products in the OrisTM cell-based assay line that enable life science researchers to study cell migration; a process critical to a variety of in vivo processes including tumor cell metastasis, wound healing, and tissue regeneration.
For more information: Maria Perr, MBA, M.Sc.
Director of Marketing
Ph: 608.237.1270 ext. 348